Siemens Healthineers Slumps to Fresh 52-Week Low as Twin Headwinds Crush Sentiment Ahead of Q2

Siemens Healthineers shares hit a 12-month low, down 24% in 2026, as US tariffs, currency effects, and German healthcare austerity weigh on outlook.

The selling pressure on Siemens Healthineers shows no sign of letting up. Shares of the German medical technology group tumbled to yet another 12-month trough on Wednesday, extending a losing streak that has now reached six consecutive sessions. The stock closed at €33.78, representing a decline of roughly 3.9% on the day, though intraday lows briefly touched €34.00 before sliding further.

From the start of 2026, the equity has shed approximately 24% of its value. The relative strength index has dropped to 31.6, pushing the stock into technically oversold territory — a level that typically catches the attention of short-term traders looking for a bounce.

Tariff Shock and Currency Headwinds

The fundamental picture offers little comfort. Management has flagged that fresh US tariffs are expected to weigh on adjusted EBIT by around €400 million in the current financial year. Currency effects add another €200 million to €250 million in headwinds. Despite these pressures, the company has held firm on its full-year guidance, targeting comparable revenue growth of 5% to 6% and adjusted earnings per share in a range of €2.20 to €2.40.

The diagnostics division, a core pillar of the business, contracted by 3% in the first quarter. China's anti-corruption campaign has disrupted procurement processes and lengthened sales cycles, compounding the pain from the broader slowdown in that market.

Domestic Austerity Adds to the Gloom

At home, the picture is equally challenging. The German cabinet's planned reform of statutory health insurance aims to save roughly €20 billion by 2027, with more than 40% of those cuts targeting the hospital sector. Hospitals are postponing investments in expensive imaging systems and laboratory diagnostics — the very products that form the backbone of Siemens Healthineers' revenue stream. The Hessen hospital association has already warned of a potential wave of insolvencies among clinics.

A Potential Catalyst on the Horizon

Investors are increasingly focused on a structural shift that could reshape the company's financial profile. Siemens AG, which still holds a 30% stake in Healthineers, currently provides a guarantee for up to €13.9 billion of the subsidiary's debt. Once that guarantee is removed — a formal decision could come as early as 2027 — Healthineers will need to secure its own refinancing. Morgan Stanley recently trimmed its price target to €41, a level that still implies more than 20% upside from current prices.

Barclays Capital has maintained its buy recommendation with a €55 target, drawing encouragement from the robust quarterly results posted by US rival GE Healthcare.

Bright Spots in Radiopharma

Amid the gloom, the company is pushing ahead in specialized growth areas. Siemens Healthineers will manufacture and distribute the PET imaging agent RAD101 in the US, a diagnostic tool for brain metastases, through a partnership with Radiopharm Theranostics. The move strengthens its position in the high-margin radiopharmacy segment.

The Q2 Reckoning

All eyes are now on May 7, when the board presents second-quarter results. The earnings call will be dominated by a single question: how does management plan to offset the tariff burden and the weakness in China? The market will be looking for concrete operational measures, not just reassurance. For a stock trading at multi-year lows, the stakes could hardly be higher.